Печеночная энцефалопатия: патогенез, клиника, диагностика, терапия
Аннотация
Ключевые слова
Об авторах
Ч. С. ПавловРоссия
И. В. Дамулин
Россия
В. Т. Ивашкин
Россия
Список литературы
1. Ивашкин В.Т., Маевская М.В., Федосьина Е.А. Лечение осложнений цирроза печени: Методические рекомендации для врачей. М.: Литтерра; 2011.
2. Ивашкин В.Т., Надинская М.Ю., Буеверов А.О. Печеночная энцефалопатия и методы ее метаболической коррекции. Болезни органов пищеварения 2001;1:25-7.
3. Шульпекова Ю.О., Маевская М.В. Специальные средства парентерального питания для коррекции метаболических нарушений при печеночной энцефалопатии. Фарматека: Международный медицинский журнал 2006; 1:55-60.
4. Lockwood A.H. Hepatic Encephalopathy. In: Neurology and General Medicine. Fourth ed. Ed. by M.J.Aminoff. Ch. 14. Philadelphia; 2008. Р. 265-79.
5. Stewart C.A., Menon K.V.N., Kamath P.S. Hepatic encephalopathy - diagnosis and management. In: Neurological Therapeutics Principles and Practice. Second ed. Vol. 2. Ed. by J.H.Noseworthy. Ch. 119. Abingdon: Informa Healthcare; 2006. P. 1432-40.
6. Alonso J., Cordoba J., Rovira A. Brain magnetic resonance in hepatic encephalopathy. Semin Ultrasound CT MRI 2014; 35:136-52.
7. Hassan E.A., Abd El-Rehim A.S., Seifeldein G.S., Shehata G. Minimal hepatic encephalopathy in patients with liver cirrhosis: Magnetic resonance spectroscopic brain findings versus neuropsychological changes. Arab J Gastroenterol 2014; 15:108-13.
8. Butterworth R.F. Pathophysiology of brain dysfunction in hyperammonemic syndromes: The many faces of glutamine. Mol Gen Metab 2014; 113:113-7.
9. Chavarria L., Alonso J., Garcıa-Martınez R. et al. Brain magnetic resonance spectroscopy in episodic hepatic encephalopathy. J Cerebr Blood Flow Metab 2013; 33:272-7.
10. Chavarria L., Cordoba J. Magnetic resonance of the brain in chronic and acute liver failure Metab. Brain Dis 2014; 29:937-44.
11. Razek A.A.K.A., Abdalla A., Ezzat A. et al. Minimal hepatic encephalopathy in children with liver cirrhosis: diffusion-weighted MR imaging and proton MR spectroscopy of the brain. Neuroradiology 2014; 56:885-91.
12. Ahluwalia V., Wade J.B., Heuman D.M. et al. Enhancement of functional connectivity, working memoryand inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: Implications for the gutliver-brain axis. Metab Brain Dis 2014; 29:1017-25.
13. Bathla G., Hegde A.N. MRI and CT appearances in metabolic encephalopathies due to systemic diseases in adults. Clin Radiol 2013; 68:545-54.
14. Ciecko-Michalska I., Dziedzic T., Banys R. et al. Does magnetic resonance spectroscopy identify patients with minimal hepatic encephalopathy? Neurol Neurochirurg Polska 2012; 46(5):436-42.
15. Conn H.O., Leevy C.M., Vlahcevic Z.R. et al. Comparison of lactulose and neomycin in the treatment of chronic portalsystemic encephalopathy: a double blind controlled trial. Gastroenterology 1977; 72:573-83.
16. Orlandi F., Freddara U., Candelaresi M.T. et al. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 1981; 26:498-506.
17. Strauss E., Tramote R., Silva E.P. et al. Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 1992; 39:542-5.
18. Tromm A., Griga T., Greving I. et al. Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Hepatogastroenterology 2000; 47:473-7.
19. Morgan M.H., Read A.E., Speller D.C. Treatment of hepatic encephalopathy with metronidazole. Gut 1982; 23:1-7.
20. Tarao K., Ikeda T., Hayashi K. et al. Successful use of vancomycin hydrochloride in the treatment of lactulose resistant chronic hepatic encephalopathy. Gut 1990; 31:702-6.
21. Di Piazza S., Gabriella F.M., Valenza L.M. et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991; 23:403-7.
22. Pedretti G., Calzetti C., Missale G., Fiaccadori F. Rifaximin versus neomycin on hyperammonemia in chronic portal systemic encephalopathy of cirrhotics: a double-blind, randomized trial. Ital J Gastroenterol 1991; 23:175-8.
23. Bucci L., Palmieri G.C. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 1993; 13:109-18.
24. Mas A., Rodes J., Sunyer L. et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 2003; 38:51-8.
25. Leevy C.B., Phillips J.A. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 2007; 52:737-41.
26. Neff G.W., Kemmer N., Zacharias V.C. et al. Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 2006; 38:3552-5.
27. Spiegel B., Huang E., Esrailian E. Is rifaximin costeffective in the management of hepatic encephalopathy? Gastroenterology 2006; 130:A-806. Abstract M1031.
Для цитирования:
Павлов Ч.С., Дамулин И.В., Ивашкин В.Т. Печеночная энцефалопатия: патогенез, клиника, диагностика, терапия. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(1):44-53. https://doi.org/10.22416/1382-4376-2016-26-1-44-53
For citation:
Pavlov C.S., Damulin I.V., Ivashkin V.T. Hepatic encephalopathy: pathogenesis, clinical presentation, diagnostics, treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(1):44-53. (In Russ.) https://doi.org/10.22416/1382-4376-2016-26-1-44-53

Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.